文献速递前列腺癌

神经内分泌前列腺癌进展的分子模型

Molecular model for neuroendocrine prostate cancer progression.
PubMed 文献 · BJU Int · 2018-04-24

本文为综述,围绕神经内分泌前列腺癌(NEPC)的驱动因素与促进因素,提出其进展由三个协同过程构成:强效雄激素受体(AR)抑制下腺癌细胞获得谱系可塑性、神经内分泌特异性转分化因子诱导NE谱系、增殖因子支持克隆扩增与肿瘤再增殖。文章还梳理了各主要贡献因素的作用并指出潜在靶向治疗机会。

要点

  • 强效AR通路抑制剂广泛应用使治疗诱导性NEPC发病率上升。
  • NEPC进展涉及谱系可塑性、NE转分化与克隆扩增三个协同过程。
  • 综述识别了NEPC主要贡献因素对应的潜在靶向治疗机会。

核心结论

  • 治疗诱导性NEPC由谱系可塑性、NE特异性转分化与增殖因子支持的克隆扩增三个协同过程驱动,是AR非依赖的侵袭性致死亚型。

研究设计与样本

  • 综述,梳理NEPC主要驱动因素与促进因素及其在疾病进展中的作用。

主要发现

  • 去势抵抗腺癌细胞在强效AR抑制的选择压力下获得谱系可塑性,转变为AR非依赖肿瘤细胞。
  • NE特异性转分化因子诱导前列腺癌细胞的NE谱系,并在增殖因子支持下促成克隆扩增与肿瘤再增殖为NEPC。
  • 治疗耐药机制包括AR信号通路改变、AR信号旁路机制和AR非依赖克隆演化,后者可导致NEPC。
  • 强效AR通路抑制剂的广泛使用使治疗诱导性NEPC发病率上升。

临床怎么用

  • 关注强效AR通路抑制剂治疗中出现AR非依赖进展、提示NEPC可能的患者。
  • 基于NEPC三大协同过程识别潜在靶向治疗机会,用于个体化治疗探索。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Prostate cancer (PCa) is the most common form of cancer in men in the developed world and the second leading cause of cancer-related deaths. While advanced PCa is initially controlled with hormonal therapies targeting the androgen receptor (AR) pathway, recurrence occurs because of the emergence of lethal castration-resistant PCa (CRPC). Despite newer AR pathway inhibitors that prolong survival, resistance still emerges, most often with rising PSA levels indicative of AR-driven activity, but increasingly as non-AR-driven cancer. Treatment resistance mechanisms include AR-signalling pathway alterations, AR-signalling bypass mechanisms, and AR-independent clonal evolution. The latter mechanism can lead to the emergence of neuroendocrine prostate cancer (NEPC), an aggressive lethal subtype of PCa. The incidence of treatment-induced NEPC is rising because of the widespread use of more potent AR pathway inhibitors. This comprehensive review of major NEPC drivers and facilitators defines three coordinated processes contributing to NEPC progression. Specifically, castration-resistant adenocarcinoma cells gain lineage plasticity under selective pressures of potent AR suppression to transform into AR-independent tumour cells. In concert, neuroendocrine (NE)-specific transdifferentiation factors induce NE lineage of these PCa cells, which, with support of increased proliferation factors, contributes to clonal expansion and tumour repopulation into NEPC. We examine the roles of each of the major NEPC contributors during the disease progression and identify potential therapeutic opportunities for targeted therapies.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Chen R, Dong X, Gleave M, et al. Molecular model for neuroendocrine prostate cancer progression. BJU Int. 2018. PMID: 29569310. doi:10.1111/bju.14207

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。